Evaluation of chloramphenicol derivative N-phenyl 2, 2 dichloroacetamide anticancer and antibacterial properties.

IF 3 Q2 PHARMACOLOGY & PHARMACY

Therapeutic delivery Pub Date : 2025-05-01 Epub Date: 2025-03-10 DOI:10.1080/20415990.2025.2476928

Arwa Al Khatib, Anas Abed, Hamdi Nsairat, Mohamed El-Tanani, Muhammad Yaqoob, Hisham Al-Obaidi

{"title":"Evaluation of chloramphenicol derivative N-phenyl 2, 2 dichloroacetamide anticancer and antibacterial properties.","authors":"Arwa Al Khatib, Anas Abed, Hamdi Nsairat, Mohamed El-Tanani, Muhammad Yaqoob, Hisham Al-Obaidi","doi":"10.1080/20415990.2025.2476928","DOIUrl":null,"url":null,"abstract":"Aims: This study aimed to develop microparticles of N-phenyl-2,2-dichloroacetamide (PDA), a chloramphenicol derivative with potential antibacterial and anticancer properties, to improve drug release and selectivity while reducing toxicity.Materials & methods: PDA microparticles were prepared via spray-drying using L-leucine, Trehalose, and Mannitol. The particles were characterized for size, drug release, antibacterial activity, and cytotoxicity against A549 cancer cells and fibroblasts.Results: PDA formulations exhibited controlled release and enhanced selectivity for cancer cells. S1 showed antibacterial activity against S. aureus. L-leucine formulations had reduced toxicity to normal fibroblasts.Conclusions: PDA microparticles offer potential as safer, targeted antibacterial and anticancer therapies, providing controlled release and reduced side effects.","PeriodicalId":22959,"journal":{"name":"Therapeutic delivery","volume":" ","pages":"431-445"},"PeriodicalIF":3.0000,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12135691/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Therapeutic delivery","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1080/20415990.2025.2476928","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/3/10 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}

引用次数: 0

Abstract

Aims: This study aimed to develop microparticles of N-phenyl-2,2-dichloroacetamide (PDA), a chloramphenicol derivative with potential antibacterial and anticancer properties, to improve drug release and selectivity while reducing toxicity.

Materials & methods: PDA microparticles were prepared via spray-drying using L-leucine, Trehalose, and Mannitol. The particles were characterized for size, drug release, antibacterial activity, and cytotoxicity against A549 cancer cells and fibroblasts.

Results: PDA formulations exhibited controlled release and enhanced selectivity for cancer cells. S1 showed antibacterial activity against S. aureus. L-leucine formulations had reduced toxicity to normal fibroblasts.

Conclusions: PDA microparticles offer potential as safer, targeted antibacterial and anticancer therapies, providing controlled release and reduced side effects.

查看原文本刊更多论文

氯霉素衍生物n -苯基2,2二氯乙酰胺的抗癌和抗菌性能评价。

目的：制备具有潜在抗菌和抗癌特性的氯霉素衍生物n -苯基-2,2-二氯乙酰胺（PDA）微颗粒，以改善药物释放和选择性，同时降低毒性。材料与方法：采用l -亮氨酸、海藻糖、甘露醇喷雾干燥法制备PDA微颗粒。颗粒的大小、药物释放、抗菌活性以及对A549癌细胞和成纤维细胞的细胞毒性进行了表征。结果：PDA制剂对肿瘤细胞具有控释和增强的选择性。S1对金黄色葡萄球菌具有抗菌活性。l -亮氨酸制剂降低了对正常成纤维细胞的毒性。结论：PDA微颗粒具有控释和减少副作用的特点，具有更安全、靶向抗菌和抗癌治疗的潜力。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Therapeutic delivery PHARMACOLOGY & PHARMACY-

CiteScore

5.50

自引率

0.00%

发文量

期刊介绍： Delivering therapeutics in a way that is right for the patient - safe, painless, reliable, targeted, efficient and cost effective - is the fundamental aim of scientists working in this area. Correspondingly, this evolving field has already yielded a diversity of delivery methods, including injectors, controlled release formulations, drug eluting implants and transdermal patches. Rapid technological advances and the desire to improve the efficacy and safety profile of existing medications by specific targeting to the site of action, combined with the drive to improve patient compliance, continue to fuel rapid research progress. Furthermore, the emergence of cell-based therapeutics and biopharmaceuticals such as proteins, peptides and nucleotides presents scientists with new and exciting challenges for the application of therapeutic delivery science and technology. Successful delivery strategies increasingly rely upon collaboration across a diversity of fields, including biology, chemistry, pharmacology, nanotechnology, physiology, materials science and engineering. Therapeutic Delivery recognizes the importance of this diverse research platform and encourages the publication of articles that reflect the highly interdisciplinary nature of the field. In a highly competitive industry, Therapeutic Delivery provides the busy researcher with a forum for the rapid publication of original research and critical reviews of all the latest relevant and significant developments, and focuses on how the technological, pharmacological, clinical and physiological aspects come together to successfully deliver modern therapeutics to patients. The journal delivers this essential information in concise, at-a-glance article formats that are readily accessible to the full spectrum of therapeutic delivery researchers.